Background: Oncogenic types of human papillomavirus (HPV) have been linked to
and was among the most costly in terms of total estimated direct medical costs (second only to HIV). This estimate encompassed costs associated with cervical abnormalities (diagnosis and management of cytologic abnormalities, preinvasive cervical neoplasia, and invasive cervical cancer) as well as costs associated with external anogenital warts.
A more recent estimate of the annual direct medical costs associated with the prevention and treatment of anogenital warts and cervical HPV-related disease put this figure at approximately $4 billion. [16] Routine cervical screenings account for over 63% of total HPV-related healthcare costs. [17] Reoccurring lesions that require repeat procedures and follow-up also contribute significantly to overall costs. [18] Recently there have been significant advances in the development of prophylactic HPV vaccines, which can prevent infection of HPV types among individuals uninfected with these types. These vaccines have the potential to significantly reduce the incidence of cervical cancer and precancerous lesions. [19, 20, 21, 22 clinical trials to be highly effective, with the potential to prevent ~70% of cervical cancer cases. Among subjects naive to a given HPV type at baseline and throughout the 3-dose vaccination, vaccine efficacy against cervical intraepithelial neoplasia (CIN) grade II-III or adenocarcinoma in situ was 99% (95% confidence interval 93% to 100%). [25, 26] Results of trials of Cervarix® and Gardasil® have demonstrated efficacy against cervical infection and cervical lesions associated with HPV-16/18 for up to 8.4 years and 5 years, respectively. [27] Gardasil® also has demonstrated efficacy against HPV types 6 and 11 (the most important HPV types causing genital warts), although these do not progress to CIN grade 2/3 or cervical cancer. Vaccines, therefore, may help to decrease costs associated with screening and management of cervical abnormalities.
To our knowledge, only one previous study assessed the incidence and economic burden of CIN in a US commercially insured population. [28] It is difficult to identify the incidence of CIN in national databases for several reasons. First, administrative database diagnosis codes may not be reliable (i.e., databases may contain unspecified codes, and accurate diagnostic codes are not always required for billing). Using procedural codes to estimate the number of cytology pathologies performed related to HPV and cervical neoplasia/cancer outcomes from health plans may be more reliable. [29] The impact of vaccination can be observed in reductions in procedures, but procedure coding may not provide a reliable estimate either, as it is primarily used to ensure reimbursement. Administrative database codes are accessible across a wide range of health plans. While the results associated with the data in this study must be interpreted with caution, they offer a perspective that can readily serve as a benchmark for future assessments of the impact of vaccines.
The objective of this study is to assess the frequency and costs of HPV-related diagnostic and treatment procedures performed prior to introduction of HPV vaccination.
While primary screening represents the highest cost burden, this study focuses on follow-up costs associated with diagnosis and abnormalities. By doing so, benchmarks can be established that enable future evaluations of the impact of HPV vaccination on resource consumption. We studied healthcare costs associated with procedures related to disease most likely attributable to HPV in the United States using a large, geographically diverse health claims database. A wide range of procedures were examined from 2001 to 2006. The rates of use and direct costs associated with these procedures were evaluated. We did not differentiate between oncogenic and nononcogenic HPV types.
MATERIALS AND METHODS

Data Source
We used retrospectively collected claims data from OptumInsight's proprietary research database. The database, which has been described in several published studies, [28, 30, 31] Claims data are de-identified, and each enrollee is assigned a randomly generated unique identifier before being placed in the database. The study was conducted using data determined to be statistically de-identified in accordance with established privacy guidelines under the Health Insurance and Portability and Accountability Act, making a separate Institutional Review Board approval unnecessary.
Study Population
All procedures related to disease most likely due to HPV occurring from January 1, inpatient procedure costs were calculated from claims for all services on and between admission and discharge dates. This approach allowed for the inclusion of costs specific to the procedure as well as for services related to the procedure, such as physician visits and application of anesthesia. Median costs are presented to minimize the impact of skewing in the distribution of cost data, and mean (SD) costs are presented to reflect the range of costs.
RESULTS
Population Description
Over the entire analytic period 
2006, respectively. With the exception of ECC, the rates of HPV-related diagnostic procedures reached a peak among enrollees aged 20-24 years old, and followed a downward trend across the older age groups (Figure 3 , Appendix Table B) . ECC experienced its peak among 25-to 29-year-olds. Diagnostic procedures were used infrequently for those under age 15. Rates of treatment procedures were highest among 20-to 29-year-olds and followed a pattern of decline in older age groups, similar to what was observed for diagnostic procedures (Appendix Table B ). Hysterectomy, an exception, was highest in the 45-to 49-year age group (30,143 women, or 1.8% of those aged 45-49).
Appendix Table C (Table 3 ).
Costs varied significantly by patient age for 3 treatments and 1 diagnostic procedure (Appendix Table D We also examined median and mean costs per procedure among women targeted for HPV vaccination (Appendix Table E Rates of HPV-related diagnostic procedures remained mostly stable. The most frequently performed diagnostic procedure was colposcopy with endocervical curettage, with the highest rates occurring among 20-to 24-year-olds. With the exception of ECC, rates of HPV-related diagnostic procedures reached a peak among enrollees aged 20-24, and followed a downward trend across the older age groups.
Biopsy was the most expensive diagnostic procedure, with a median cost ranging from Our analysis for this subset was conducted in 2005, the year prior to the implementation of HPV vaccinations. HPV vaccination is expected to have an effect on the costs of procedures related to disease most likely due to HPV. [35] The cost-effectiveness of vaccination depends on the duration of immunity (which cannot be predicted) and whether vaccination affects subsequent screening delay or frequency. [36] Modeling studies comparing the cost-effectiveness of vaccination when various screening regimens are used suggest that vaccination is more cost-effective when screening is started later and is performed less frequently. [36, 37] Therefore, use of HPV vaccination may have the potential to lead to substantial cost savings for HPV-related diagnostic and treatment procedures, due to reduced need for screening and improved prevention.
Furthermore, our study population included a substantial number of enrollees younger than 21 years of age, and, according to 2009 ACOG guidelines, [32] cervical cancer screening should begin at age 21. New 2012 U.S. Preventive Services Task Force screening guidelines recommend that women aged 21 to 29 should be screened by cytology every 3 years, and women aged 30 to 65 should be screened either by cytology every 3 years or, for those who want a longer screening interval, co-testing with cytology and HPV testing every 5 years. [38] Several study limitations are present that impede our ability to make projections relating to overall costs of care and trends in procedure rates. Analyses were performed using claims associated with the procedure alone. This approach may underestimate costs, as it excludes codes submitted by multiple providers for ancillary services associated For patients with more than one relevant procedure code on a single day, each code was treated separately, and rates were determined individually for each specific procedure code. While physicians should use combined codes when appropriate (i.e., billing colposcopy with ECC using the single procedure code rather than separate codes for colposcopy and for ECC), it is possible that variations in billing practices occurred over the 6-year study period and that codes were not always appropriately used.
Further, some codes were not available in early years, while others were eliminated during the study period.
Finally, these results pertain to a commercially insured population and cannot necessarily be extrapolated to Medicare-insured or uninsured populations. However, these study patients were younger than 65 and therefore differ substantially from Medicare patients based on age alone.
CONCLUSIONS
This study provides a current perspective on rates of procedures related to disease most likely due to HPV and associated costs, and establishes benchmarks for a commercially insured female population as well as for age-specific cohorts The data presented here may be useful in cost-effectiveness analyses and to guide decision makers evaluating how best to optimize primary and secondary prevention strategies. Further research is needed to examine factors that may have an impact on cost, such as provider and patient compliance with screening and management guidelines.
ACKNOWLEDGMENTS
The authors thank Victoria Porter, medical writer, and Randall Gerdes, research analyst, both employees of OptumInsight, for their assistance with the preparation of this manuscript. 
